Loading, Please Wait...

CST: 12/11/2019 18:37:38   

Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk

105 Days ago

SEATTLE, July 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced the online launch of company CEO Steven Quay’s Tedx UofW Talk, “How to Be Smart When You’re Dense: Preventing Breast Cancer by 2030.” 

In the Tedx UofW talk, Steven Quay, M.D., Ph.D., Atossa’s Chief Executive Officer outlines the journey of Atossa Genetics in identifying improved ways to identify women at high risk of breast cancer, using mammography to identify dense breast tissue.  Dr. Quay also details his experience with triumph, failure and perseverance while trying to prevent one of the world’s most common diseases: breast cancer. He emphasizes the need for unshaken efforts to solve such complex problems, and ways that he and his team are doing so in breast cancer research.

The talk has been posted online at https://www.youtube.com/watch?v=hK4PlbYE_5M&list=PLsRNoUx8w3rNCo4uCVXiNDFZLiKrIOQ1J&index=5 and can also be accessed via the company’s website at www.atossagenetics.com.

“I am grateful for having had the opportunity to address our approach to breast cancer as something that, like cervical cancer, has the potential to be completely eradicated over time.  It was an honor to participate in this University of Washington program and I hope the information provided helps those who participated in the event, as well as those who view it online,” commented Dr. Quay.

Steven Quay is the founder of Seattle-based Atossa Genetics, Inc., dedicated to breast cancer prevention. He received a Ph.D. in Biological Chemistry and a M.D. from the University of Michigan, a postdoc at MIT and Harvard, and he was a faculty member at Stanford Medical School.  His contributions to medicine, cancer, and biochemistry have been cited more than 9,300 times, putting him in the top 1% of the world’s scientists.  Since entering the biotech industry in 1983, he has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 U.S. patents.  Over 80 million people have benefited from the medicines he invented.  His current passion involves the prevention of the two million yearly breast cancer cases worldwide.  This talk was given at a TEDx event using the TED conference format but independently organized by a local community.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa's drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 866-893-4927
kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516.222.2560
scottg@CoreIR.com

Is your business listed correctly on America’s largest city directory network of 1,000 portals?